Top

Published in:

01-06-2019 | Metastasis | Original Article

Clonal analysis of early-stage bilateral papillary thyroid cancer identifies field cancerization

Authors: Xingyun Su, Shitu Chen, Kuifeng He, Zhuochao Mao, Jiaying Ruan, Jie Zhou, Xiaodong Teng, Judy Jin, Thomas J. Fahey III, Weibin Wang, Lisong Teng

Published in: Endocrine | Issue 3/2019

Abstract

Introduction

Bilaterality is a newly identified indicator for aggressive tumor behavior and poor outcome in papillary thyroid cancer. However, the clonal origin of these bilateral tumors remains unclear.

Methods

Here we analyzed 28 pairs of early-stage papillary thyroid cancers (stage I–II without extra-thyroidal extension, lymph node metastasis or distant metastasis) that underwent surgery at First Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China). Genomic DNA was extracted from paraffin-embedded tissues after microdissection and analyzed for BRAF mutation and X-chromosome inactivation.

Results

A total of 16 patients (16/28, 57.1%) harbored different BRAF status in bilateral tumors. Fourteen patients were available for X-chromosome inactivation assay and 10 of them achieved informative results. Bilateral tumors from four cases had distinct patterns of X-chromosome inactivation. Combining the results of X-chromosome inactivation and BRAF analysis, we demonstrated that at least 64.3% (18/28) cases harbored discordant X-chromosome inactivation or BRAF status, indicating their independent clonal origin in bilateral tumors.

Conclusions

The present study confirms “field cancerization” in early-stage bilateral thyroid cancers, suggesting that these subtype papillary thyroid cancers should be treated as independent and localized tumors.

R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018). https://doi.org/10.3322/caac.21442 CrossRefPubMed

K.D. Miller, R.L. Siegel, C.C. Lin, A.B. Mariotto, J.L. Kramer, J.H. Rowland, K.D. Stein, R. Alteri, A. Jemal, Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66(4), 271–289 (2016). https://doi.org/10.3322/caac.21349 CrossRefPubMed

M.R. Haymart, M. Banerjee, A.K. Stewart, R.J. Koenig, J.D. Birkmeyer, J.J. Griggs, Use of radioactive iodine for thyroid cancer. JAMA 306(7), 721–728 (2011). https://doi.org/10.1001/jama.2011.1139 CrossRefPubMedPubMedCentral

S. Markovina, P.W. Grigsby, J.K. Schwarz, T. DeWees, J.F. Moley, B.A. Siegel, S.M. Perkins, Treatment approach, surveillance, and outcome of well-differentiated thyroid cancer in childhood and adolescence. Thyroid 24(7), 1121–1126 (2014). https://doi.org/10.1089/thy.2013.0297 CrossRefPubMed

S.C. Pitt, R.S. Sippel, H. Chen, Contralateral papillary thyroid cancer: does size matter? Am. J. Surg. 197(3), 342–347 (2009). https://doi.org/10.1016/j.amjsurg.2008.09.011 CrossRefPubMedPubMedCentral

J.L. Pasieka, N.W. Thompson, M.K. McLeod, R.E. Burney, M. Macha, The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J. Surg. 16(4), 711–716 (1992). discussion 716-717CrossRefPubMed

B.S. Koo, H.S. Lim, Y.C. Lim, Y.H. Yoon, Y.M. Kim, Y.H. Park, K.S. Rha, Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Ann. Surg. Oncol. 17(4), 1101–1105 (2010). https://doi.org/10.1245/s10434-009-0906-6 CrossRefPubMed

W. Wang, W. Zhao, H. Wang, X. Teng, H. Wang, X. Chen, Z. Li, X. Yu, T.J. Fahey 3rd, L. Teng, Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann. Surg. Oncol. 19(1), 31–36 (2012). https://doi.org/10.1245/s10434-011-2096-2 CrossRefPubMed

W. Wang, X. Su, K. He, Y. Wang, H. Wang, H. Wang, Y. Zhao, W. Zhao, R. Zarnegar, T.J. Fahey 3rd, X. Teng, L. Teng, Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: an updated study with more than 2000 consecutive patients. Cancer 122(2), 198–206 (2016). https://doi.org/10.1002/cncr.29689 CrossRefPubMed

10.

M.F. Lyon, Sex chromatin and gene action in the mammalian X-chromosome. Am. J. Hum. Genet. 14, 135–148 (1962)PubMedPubMedCentral

11.

C. Swanton, Intratumor heterogeneity: evolution through space and time. Cancer Res. 72(19), 4875–4882 (2012). https://doi.org/10.1158/0008-5472.CAN-12-2217 CrossRefPubMedPubMedCentral

12.

M. Gerlinger, A.J. Rowan, S. Horswell, M. Math, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, S. Begum, N.Q. McDonald, A. Butler, D. Jones, K. Raine, C. Latimer, C.R. Santos, M. Nohadani, A.C. Eklund, B. Spencer-Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P.A. Futreal, C. Swanton, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883–892 (2012). https://doi.org/10.1056/NEJMoa1113205 CrossRefPubMedPubMedCentral

13.

E.C. de Bruin, N. McGranahan, R. Mitter, M. Salm, D.C. Wedge, L. Yates, M. Jamal-Hanjani, S. Shafi, N. Murugaesu, A.J. Rowan, E. Gronroos, M.A. Muhammad, S. Horswell, M. Gerlinger, I. Varela, D. Jones, J. Marshall, T. Voet, P. Van Loo, D.M. Rassl, R.C. Rintoul, S.M. Janes, S.M. Lee, M. Forster, T. Ahmad, D. Lawrence, M. Falzon, A. Capitanio, T.T. Harkins, C.C. Lee, W. Tom, E. Teefe, S.C. Chen, S. Begum, A. Rabinowitz, B. Phillimore, B. Spencer-Dene, G. Stamp, Z. Szallasi, N. Matthews, A. Stewart, P. Campbell, C. Swanton, Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346(6206), 251–256 (2014). https://doi.org/10.1126/science.1253462 CrossRefPubMedPubMedCentral

14.

M. Xing, Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 13(3), 184–199 (2013)CrossRefPubMedPubMedCentral

15.

J.A. Knauf, X. Ma, E.P. Smith, L. Zhang, N. Mitsutake, X.H. Liao, S. Refetoff, Y.E. Nikiforov, J.A. Fagin, Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65(10), 4238–4245 (2005). https://doi.org/10.1158/0008-5472.CAN-05-0047 CrossRefPubMed

16.

Z. Lu, J. Sheng, Y. Zhang, J. Deng, Y. Li, A. Lu, J. Zhang, H. Yu, M. Zhang, Z. Xiong, H. Yan, B.H. Diplas, Y. Lu, B. Liu, Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. J. Pathol. 239(1), 72–83 (2016). https://doi.org/10.1002/path.4696 CrossRefPubMedPubMedCentral

17.

T.M. Shattuck, W.H. Westra, P.W. Ladenson, A. Arnold, Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N. Engl. J. Med. 352(23), 2406–2412 (2005). https://doi.org/10.1056/NEJMoa044190 CrossRefPubMed

18.

S.Y. Park, Y.J. Park, Y.J. Lee, H.S. Lee, S.H. Choi, G. Choe, H.C. Jang, S.H. Park, D.J. Park, B.Y. Cho, Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107(8), 1831–1838 (2006). https://doi.org/10.1002/cncr.22218 CrossRefPubMed

19.

W. Wang, H. Wang, X. Teng, H. Wang, C. Mao, R. Teng, W. Zhao, J. Cao, T.J. Fahey 3rd, L. Teng, Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. Hum. Pathol. 41(9), 1299–1309 (2010). https://doi.org/10.1016/j.humpath.2010.02.008 CrossRefPubMed

20.

R.P. McCarthy, M. Wang, T.D. Jones, R.W. Strate, L. Cheng, Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin. Cancer Res. 12(8), 2414–2418 (2006). https://doi.org/10.1158/1078-0432.CCR-05-2818 CrossRefPubMed

21.

T.J. O’Grady, M.A. Gates, F.P. Boscoe, Thyroid cancer incidence attributable to overdiagnosis in the United States 1981–2011. Int. J. Cancer 137(11), 2664–2673 (2015). https://doi.org/10.1002/ijc.29634 CrossRefPubMed

22.

C.M. Kitahara, J.A. Sosa, The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12(11), 646–653 (2016). https://doi.org/10.1038/nrendo.2016.110 CrossRefPubMed

23.

L. Klotz, Cancer overdiagnosis and overtreatment. Curr. Opin. Urol. 22(3), 203–209 (2012). https://doi.org/10.1097/MOU.0b013e32835259aa CrossRefPubMed

24.

S. Jegerlehner, J.L. Bulliard, D. Aujesky, N. Rodondi, S. Germann, I. Konzelmann, A. Chiolero, N.W. Group, Overdiagnosis and overtreatment of thyroid cancer: a population-based temporal trend study. PLoS ONE 12(6), e0179387 (2017). https://doi.org/10.1371/journal.pone.0179387 CrossRefPubMedPubMedCentral

25.

R.P. Tufano, S.I. Noureldine, P. Angelos, Incidental thyroid nodules and thyroid cancer: considerations before determining management. JAMA Otolaryngol. Head Neck Surg. 141(6), 566–572 (2015). https://doi.org/10.1001/jamaoto.2015.0647 CrossRefPubMed

26.

R.A. DeLellis, Pathology and genetics of thyroid carcinoma. J. Surg. Oncol. 94(8), 662–669 (2006). https://doi.org/10.1002/jso.20700 CrossRefPubMed

27.

N.D. Perrier, J.D. Brierley, R.M. Tuttle, Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 68(1), 55–63 (2018). https://doi.org/10.3322/caac.21439 CrossRefPubMed

28.

R.C. Allen, H.Y. Zoghbi, A.B. Moseley, H.M. Rosenblatt, J.W. Belmont, Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am. J. Hum. Genet. 51(6), 1229–1239 (1992)PubMedPubMedCentral

29.

W.D. Tilley, M. Marcelli, J.D. Wilson, M.J. McPhaul, Characterization and expression of a cDNA encoding the human androgen receptor. Proc. Natl Acad. Sci. USA 86(1), 327–331 (1989)CrossRefPubMed

30.

S. Moniz, A.L. Catarino, A.R. Marques, B. Cavaco, L. Sobrinho, V. Leite, Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. Eur. J. Endocrinol. 146(1), 27–33 (2002)CrossRefPubMed

31.

H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, P.A. Futreal, Mutations of the BRAF gene in human cancer. Nature 417(6892), 949–954 (2002). https://doi.org/10.1038/nature00766 CrossRef

32.

P.C. Nowell, The clonal evolution of tumor cell populations. Science 194(4260), 23–28 (1976)CrossRefPubMed

33.

D.P. Slaughter, H.W. Southwick, W. Smejkal, Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6(5), 963–968 (1953)CrossRefPubMed

34.

V.M. van Houten, C.R. Leemans, J.A. Kummer, J. Dijkstra, D.J. Kuik, M.W. van den Brekel, G.B. Snow, R.H. Brakenhoff, Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin. Cancer Res. 10(11), 3614–3620 (2004). https://doi.org/10.1158/1078-0432.CCR-03-0631 CrossRefPubMed

35.

K. Shiga, T. Ogawa, F. Yoshida, K. Matsuura, M. Tateda, S. Saijo, T. Miyagi, T. Kobayashi, Multiple squamous cell carcinomas of the head and neck show different phenotypes of allelic loss patterns suggesting different clonal origin of carcinogenesis. Anticancer Res. 23(5A), 3911–3915 (2003)PubMed

36.

G.H. Heppner, F.R. Miller, The cellular basis of tumor progression. Int. Rev. Cytol. 177, 1–56 (1998)PubMed

37.

H. Chai, R.E. Brown, Field effect in cancer-an update. Ann. Clin. Lab. Sci. 39(4), 331–337 (2009)PubMed

38.

W.C. Kisseberth, E.P. Sandgren, Polyclonal development of mouse mammary preneoplastic nodules. Cancer Res. 64(3), 857–863 (2004)CrossRefPubMed

39.

A.J. Merritt, K.A. Gould, W.F. Dove, Polyclonal structure of intestinal adenomas in ApcMin/+mice with concomitant loss of Apc+ from all tumor lineages. Proc. Natl Acad. Sci. USA 94(25), 13927–13931 (1997)CrossRefPubMed

40.

M.R. Novelli, J.A. Williamson, I.P. Tomlinson, G. Elia, S.V. Hodgson, I.C. Talbot, W.F. Bodmer, N.A. Wright, Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science 272(5265), 1187–1190 (1996)CrossRefPubMed

41.

D.J. Winton, M.A. Blount, B.A. Ponder, Polyclonal origin of mouse skin papillomas. Br. J. Cancer 60(1), 59–63 (1989)CrossRefPubMedPubMedCentral

Title: Clonal analysis of early-stage bilateral papillary thyroid cancer identifies field cancerization
Authors: Xingyun Su
Shitu Chen
Kuifeng He
Zhuochao Mao
Jiaying Ruan
Jie Zhou
Xiaodong Teng
Judy Jin
Thomas J. Fahey III
Weibin Wang
Lisong Teng
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Metastasis
Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Endocrine / Issue 3/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-01877-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy

Hypertriglyceridemic waist phenotype and abnormal glucose metabolism: a system review and meta-analysis

Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis

Dysbiosis of the gut microbiome is associated with thyroid cancer and thyroid nodules and correlated with clinical index of thyroid function

Expression and clinicopathological role of miR146a in thyroid follicular carcinoma

A novel mutation in INS gene linked to permanent neonatal diabetes mellitus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials